The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England.
The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England.
复制标题
DOI:
10.1126/scitranslmed.abo5395
复制
发表时间:
2022-07-06
影响因子:
17.1
通讯作者:
中科院分区:
文献类型:
--
作者:
The emergence of the B.1.1.529 (Omicron) variant caused international concern due to its rapid spread in Southern Africa. It was unknown whether this variant would replace or co-exist with (either transiently or long-term) the then-dominant Delta variant on its introduction to England. We developed a set of hierarchical logistic growth models to describe changes in the frequency of S gene target failure (SGTF) PCR tests, which was a proxy for Omicron. The doubling time of SGTF cases peaked at 1.56 days (95% CI: 1.49, 1.63) on the 5th of December, while triple positive cases were halving every 5.82 days (95% CI: 5.11, 6.67) going into Christmas 2021. We were unable to characterize the replacement of Delta by Omicron with a single rate. The replacement rate decreased by 53.56% (95% CrI: 45.38, 61.01) between the 14th and 15th of December, meaning the competitive advantage of Omicron approximately halved. Preceding the changepoint, Omicron was replacing Delta 16.24% (95% CrI: 9.72, 23.41) faster in those with two or more vaccine doses, indicative of vaccine escape being a substantial component of the competitive advantage. Despite the slowdown, Delta had almost entirely been replaced in England within a month of the first sequenced domestic case. The synchrony of changepoints across regions at various stages of Omicron epidemics suggests that the growth rate advantage was not attenuated due to biological mechanisms related to strain competition. The step-change in replacement could have resulted from behavioral changes, potentially elicited by public health messaging or policies, that differentially affected Omicron. The Omicron variant replaced the Delta variant in England despite the rate of replacement approximately halving in mid-December 2021.
登录
查看更多内容
DOI:
10.1056/nejmoa2119451
发表时间:
2022-04-21
期刊:
The New England journal of medicine
影响因子:
--
作者:
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者:
Lopez Bernal J
影响因子:
56.9
作者:
McCallum, Matthew;Czudnochowski, Nadine;Rosen, Laura E.;Zepeda, Samantha K.;Bowen, John E.;Walls, Alexandra C.;Hauser, Kevin;Joshi, Anshu;Stewart, Cameron;Dillen, Josh R.;Powell, Abigail E.;Croll, Tristan, I;Nix, Jay;Virgin, Herbert W.;Corti, Davide;Snell, Gyorgy;Veesler, David
通讯作者:
Veesler, David
影响因子:
64.5
作者:
Liu C;Ginn HM;Dejnirattisai W;Supasa P;Wang B;Tuekprakhon A;Nutalai R;Zhou D;Mentzer AJ;Zhao Y;Duyvesteyn HME;López-Camacho C;Slon-Campos J;Walter TS;Skelly D;Johnson SA;Ritter TG;Mason C;Costa Clemens SA;Gomes Naveca F;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Dold C;Temperton N;Dong T;Pollard AJ;Knight JC;Crook D;Lambe T;Clutterbuck E;Bibi S;Flaxman A;Bittaye M;Belij-Rammerstorfer S;Gilbert SC;Malik T;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Baillie V;Serafin N;Ditse Z;Da Silva K;Paterson NG;Williams MA;Hall DR;Madhi S;Nunes MC;Goulder P;Fry EE;Mongkolsapaya J;Ren J;Stuart DI;Screaton GR
通讯作者:
Screaton GR
DOI:
10.3390/v14020294
发表时间:
2022-01-30
期刊:
Viruses
影响因子:
--
作者:
Grabowski F;Kochańczyk M;Lipniacki T
通讯作者:
Lipniacki T
DOI:
10.1098/rstb.2020.0264
发表时间:
2021-07-19
期刊:
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
影响因子:
--
作者:
Pellis L;Scarabel F;Stage HB;Overton CE;Chappell LHK;Fearon E;Bennett E;Lythgoe KA;House TA;Hall I;University of Manchester COVID-19 Modelling Group
通讯作者:
University of Manchester COVID-19 Modelling Group